LB Pharmaceuticals Inc Common Stock (LBRX) Stock Analysis & Investment Frameworks
LB Pharmaceuticals Inc Common Stock (LBRX) stock analysis on Invetso. Review LB Pharmaceuticals Inc Common Stock’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
LB Pharmaceuticals Inc Common Stock Company Overview
- Exchange: NASDAQ Global Select
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
LB Pharmaceuticals Inc Common Stock Key Financial Metrics
- Market Cap: $1.27B
- Revenue: $N/A
- ROE: -25.91%
- ROIC: -28.07%
- Dividend Yield: N/A
About LB Pharmaceuticals Inc Common Stock
This biopharmaceutical firm is currently in the clinical development stage, concentrating on the creation of innovative treatments for neuropsychiatric disorders such as schizophrenia and bipolar depression. Central to their pipeline is LB-102, their primary investigational drug, which is a methylated variant of amisulpride.